These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 21762078)

  • 1. Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia.
    Mummery A; Narendran A; Lee KY
    Curr Cancer Drug Targets; 2011 Sep; 11(7):882-93. PubMed ID: 21762078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased activity of histone deacetylases in childhood acute lymphoblastic leukaemia and acute myeloid leukaemia: support for histone deacetylase inhibitors as antileukaemic agents.
    Sonnemann J; Gruhn B; Wittig S; Becker S; Beck JF
    Br J Haematol; 2012 Sep; 158(5):664-6. PubMed ID: 22686282
    [No Abstract]   [Full Text] [Related]  

  • 3. Genetic and Epigenetic Targeting Therapy for Pediatric Acute Lymphoblastic Leukemia.
    Xu H; Yu H; Jin R; Wu X; Chen H
    Cells; 2021 Nov; 10(12):. PubMed ID: 34943855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition.
    Bachmann PS; Piazza RG; Janes ME; Wong NC; Davies C; Mogavero A; Bhadri VA; Szymanska B; Geninson G; Magistroni V; Cazzaniga G; Biondi A; Miranda-Saavedra D; Göttgens B; Saffery R; Craig JM; Marshall GM; Gambacorti-Passerini C; Pimanda JE; Lock RB
    Blood; 2010 Oct; 116(16):3013-22. PubMed ID: 20647567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-leukemic effects of histone deacetylase (HDAC) inhibition in acute lymphoblastic leukemia (ALL) cells: Shedding light on mitigating effects of NF-κB and autophagy on panobinostat cytotoxicity.
    Mehrpouri M; Safaroghli-Azar A; Pourbagheri-Sigaroodi A; Momeny M; Bashash D
    Eur J Pharmacol; 2020 May; 875():173050. PubMed ID: 32142770
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Research Advances in the Use of Histone Deacetylase Inhibitors for Epigenetic Targeting of Cancer.
    Bai Y; Ahmad D; Wang T; Cui G; Li W
    Curr Top Med Chem; 2019; 19(12):995-1004. PubMed ID: 30686256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Histone deacetylase inhibitors - molecular mechanisms of actions and clinical applications].
    Grabarska A; Dmoszyńska-Graniczka M; Nowosadzka E; Stepulak A
    Postepy Hig Med Dosw (Online); 2013 Aug; 67():722-35. PubMed ID: 24018438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigenetic targeting of Notch1-driven transcription using the HDACi panobinostat is a potential therapy against T-cell acute lymphoblastic leukemia.
    Waibel M; Vervoort SJ; Kong IY; Heinzel S; Ramsbottom KM; Martin BP; Hawkins ED; Johnstone RW
    Leukemia; 2018 Jan; 32(1):237-241. PubMed ID: 28914259
    [No Abstract]   [Full Text] [Related]  

  • 9. Histone deacetylase inhibitors and epigenetic regulation in lymphoid malignancies.
    Markozashvili D; Ribrag V; Vassetzky YS
    Invest New Drugs; 2015 Dec; 33(6):1280-91. PubMed ID: 26423245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone Deacetylase Inhibitors in Cancer Therapy.
    Sun Y; Sun Y; Yue S; Wang Y; Lu F
    Curr Top Med Chem; 2018; 18(28):2420-2428. PubMed ID: 30526462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic targeting of histone deacetylase: therapeutic potential in Parkinson's disease?
    Harrison IF; Dexter DT
    Pharmacol Ther; 2013 Oct; 140(1):34-52. PubMed ID: 23711791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Romidepsin enhances the efficacy of cytarabine
    Cheung LC; Cruickshank MN; Hughes AM; Singh S; Chua GA; Ford J; Ferrari E; Oommen J; Malinge S; Lock RB; Kees UR; Kotecha RS
    Haematologica; 2019 Jul; 104(7):e300-e303. PubMed ID: 30679330
    [No Abstract]   [Full Text] [Related]  

  • 13. Role of Histone Deacetylases (HDACs) in Epilepsy and Epileptogenesis.
    Citraro R; Leo A; Santoro M; D'agostino G; Constanti A; Russo E
    Curr Pharm Des; 2017; 23(37):5546-5562. PubMed ID: 29076408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Histone deacetylase 10, a potential epigenetic target for therapy.
    Cheng F; Zheng B; Wang J; Zhao G; Yao Z; Niu Z; He W
    Biosci Rep; 2021 Jun; 41(6):. PubMed ID: 33997894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histone Deacetylase Inhibitors as Multitarget-Directed Epi-Drugs in Blocking PI3K Oncogenic Signaling: A Polypharmacology Approach.
    Ranganna K; Selvam C; Shivachar A; Yousefipour Z
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33147762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histone deacetylation in epigenetics: an attractive target for anticancer therapy.
    Mai A; Massa S; Rotili D; Cerbara I; Valente S; Pezzi R; Simeoni S; Ragno R
    Med Res Rev; 2005 May; 25(3):261-309. PubMed ID: 15717297
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The potential role of epigenetic therapy in multiple myeloma.
    Smith EM; Boyd K; Davies FE
    Br J Haematol; 2010 Mar; 148(5):702-13. PubMed ID: 19912222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epigenetic regulation of miR-200 as the potential strategy for the therapy against triple-negative breast cancer.
    Mekala JR; Naushad SM; Ponnusamy L; Arivazhagan G; Sakthiprasad V; Pal-Bhadra M
    Gene; 2018 Jan; 641():248-258. PubMed ID: 29038000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multimodal HDAC Inhibitors with Improved Anticancer Activity.
    Schobert R; Biersack B
    Curr Cancer Drug Targets; 2018; 18(1):39-56. PubMed ID: 28176653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of HDACs inhibitors in childhood and adolescence acute leukemias.
    Masetti R; Serravalle S; Biagi C; Pession A
    J Biomed Biotechnol; 2011; 2011():148046. PubMed ID: 21318168
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.